Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Heart failure (HF) has been recognized as a common complication of diabetes, with a
prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data …

The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the previous consensus statements on the management of …

Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the previous consensus statements on the …

OBJECTIVE People with type 2 diabetes may have insufficient or prolonged sleep that could
accelerate cardiovascular disease (CVD) onset, but existing evidence from prospective …

People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure,
atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent …

Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type
2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor …

Patients with type 2 diabetes mellitus (T2DM) can have multiple comorbidities and
premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart …